Drug Profile
JNJ 54728518
Alternative Names: JNJ-54728518Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Janssen Pharmaceuticals
- Developer Johnson & Johnson Innovative Medicine
- Class Anorectics; Drug conjugates; Gastrointestinal hormones; Glucagon-like peptides; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon like peptide receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Aug 2019 No recent reports of development identified for phase-I development in Obesity in USA
- 28 Aug 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA